Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Clodronate→

Clodronate Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
10596-23-3
Molecular formula
CH4Cl2O6P2
Molecular weight
244.89 g/mol
Drug class
Non-nitrogen-containing bisphosphonateantiresorptive agent
Mechanism of action
Binds to bone mineral and inhibits osteoclastic bone resorption and hydroxyapatite crystal formation/dissolution, reducing bone turnover.
Indications / reported uses
  • Management of osteolytic lesions, hypercalcaemia and bone pain associated with skeletal metastases in patients with breast carcinoma or multiple myeloma; the exact formulation and indication are product-specific

Sources: UK SmPC — Loron (clodronate disodium) · NCI Drug Dictionary — Clodronate disodium

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Non-nitrogen-containing bisphosphonate; antiresorptive agent

Mechanism of action

Binds to bone mineral and inhibits osteoclastic bone resorption and hydroxyapatite crystal formation/dissolution, reducing bone turnover.

General use cases

  • Management of osteolytic lesions, hypercalcaemia and bone pain associated with skeletal metastases in patients with breast carcinoma or multiple myeloma; the exact formulation and indication are product-specific

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Clodronate Environmental Risk Assessment (ERA) (the Clodronate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.